PIP-D

Performance Improvement Program in Surgical Pathology

SURV

EYS

2012

AN

D A

NA

TOM

IC P

ATH

OLO

GY

EDUC

ATIO

N P

ROG

RAM

S

2012 PIP/PIPW-D

PARTICIPANT SUMMARY Program Update This report summarizes the diagnostic responses for set D of the 2012 Performance

Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Mary Beth Beasley, MD FCAP, Chair Philip A. Branton, MD FCAP, Vice Chair

Aleodor Alexandru Andea, MBA, MD FCAP Noel A. Brownlee, MD, PhD FCAP Brad B. Bryan, MD FCAP Liang Cheng, MD FCAP Simion Ion Chiosea, MD FCAP William V. Chopp, MD FCAP Byron E. Crawford, MD FCAP Rajan Dewar, MD, PhD FCAP H. Parry Dilworth, MD FCAP

Megan K. Dishop, MD FCAP Julie C. Fanburg-Smith, MD FCAP Alyssa M. Krasinskas, MD FCAP Tamera J. Lillemoe, MD FCAP Daniel J. Luthringer, MD FCAP Rochelle Simon, MD FCAP Nichole Lee Steidler, MD FCAP Saul Suster, MD FCAP Thomas S. Winokur, MD FCAP

Cas

e #

2012

-31

Diagnosis (2300) Solid-pseudopapillary neoplasm PIP Participants PIPW Participants Code Diagnosis No. % No. % 1344 Pancreatic acinar cell carcinoma 80 1.3 8 12.3 1305 Pancreatic ductal adenocarcinoma 7 0.1 0 0.0 2298 Pancreatic neuroendocrine tumor 58 1.0 5 7.7 1304 Pancreatic pseudocyst 1 0.1 2 3.1 2418 Pancreatoblastoma 18 0.3 1 1.5 2300 Solid-pseudopapillary neoplasm 5858 97.2 49 75.4

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2486 43.8 002 1544 27.3 003 Satisfactory 1454 25.7 004 165 2.9 005 Unsatisfactory 17 0.3

Cas

e #

2012

-32

Diagnosis (2504) Plexiform neurofibroma PIP Participants PIPW Participants Code Diagnosis No. % No. % 2249 Intraneural perineurioma 40 0.7 6 9.2 2159 Malignant peripheral nerve sheath tumor 2 0.1 1 1.5 2806 Palisaded encapsulated neuroma 40 0.7 4 6.2 2504 Plexiform neurofibroma 5838 96.7 52 80.0 1206 Plexiform schwannoma 107 1.8 2 3.1

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2738 48.7 002 1450 25.8 003 Satisfactory 1305 23.3 004 110 2.0 005 Unsatisfactory 9 0.2

1

Cas

e #

2012

-33

Diagnosis (1376) Mesenchymal dysplasia PIP Participants PIPW Participants Code Diagnosis No. % No. % 2807 Chorangioma 11 0.2 3 4.8 2520 Chorangiosis 18 0.3 1 1.6 1247 Hemorrhagic endovasculitis 6 0.1 0 0.0 1586 Hydatidiform mole, complete 66 1.1 1 1.6 1253 Hydatidiform mole, partial 385 6.4 19 30.1 1376 Mesenchymal dysplasia 5231 86.9 31 49.2 2808 Placental hydrops 287 4.8 8 12.7 2055 Villitis of unknown etiology 10 0.2 0 0.0

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2559 45.7 002 1522 27.2 003 Satisfactory 1397 25.0 004 110 2.0 005 Unsatisfactory 8 0.1

Cas

e #

2012

-34

Diagnosis (2334) Mantle cell lymphoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 2809 Follicular lymphoma, low grade 7 0.1 0 0.0 1630 Hairy cell leukemia 8 0.1 1 1.6 2334 Mantle cell lymphoma 5950 98.8 55 87.3 2411 Small lymphocytic lymphoma 21 0.4 0 0.0 1990 Splenic marginal zone lymphoma 35 0.6 7 11.1

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2317 41.4 002 1498 26.8 003 Satisfactory 1545 27.7 004 211 3.8 005 Unsatisfactory 17 0.3

2

Cas

e #

2012

-35

Diagnosis (1799) Hibernoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 1691 Adult rhabdomyoma 3 0.1 0 0.0 2141 Granular cell tumor 15 0.3 0 0.0 1799 Hibernoma 5993 99.4 60 95.2 2443 Lipoma 6 0.1 1 1.6 2444 Liposarcoma 1 0.1 2 3.2

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2908 51.9 002 1318 23.5 003 Satisfactory 1279 22.8 004 90 1.6 005 Unsatisfactory 13 0.2

Cas

e #

2012

-36

Diagnosis (2461) Dysgerminoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 2677 Clear cell carcinoma of ovary 1 0.1 0 0.0 2454 Diffuse large B-cell lymphoma 4 0.1 0 0.0 2461 Dysgerminoma 6012 99.7 62 100.0 2046 Metastatic renal clear cell carcinoma 2 0.1 0 0.0

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2793 50.2 002 1377 24.7 003 Satisfactory 1301 23.3 004 97 1.7 005 Unsatisfactory 7 0.1

3

Cas

e #

2012

-37

Diagnosis (1487) Extranodal marginal zone B-cell lymphoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 1487 Extranodal marginal zone B-cell

lymphoma 5954 98.9 51 83.6

1471 Lymphocytic interstitial pneumonia 10 0.2 2 3.3 2810 Lymphomatoid granulomatosis 8 0.1 4 6.6 2334 Mantle cell lymphoma 44 0.7 3 4.9 1015 Nodular lymphoid hyperplasia 6 0.1 1 1.6

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2674 47.7 002 1381 24.6 003 Satisfactory 1390 24.8 004 145 2.6 005 Unsatisfactory 18 0.3

Cas

e #

2012

-38

Diagnosis (2483) Fibrolamellar hepatocellular carcinoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 2483 Fibrolamellar hepatocellular carcinoma 5961 98.9 39 63.9 2484 Focal nodular hyperplasia 43 0.7 22 36.1 1931 Metastatic adenocarcinoma 0 0.0 0 0.0 1674 Metastatic melanoma 2 0.1 0 0.0 2333 Scirrhous variant of conventional

hepatocellular carcinoma 20 0.3 0 0.0

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2630 47.0 002 1433 25.6 003 Satisfactory 1386 24.7 004 142 2.5 005 Unsatisfactory 12 0.2

4

Cas

e #

2012

-39

Diagnosis (2445) Myelolipoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 2443 Lipoma 65 1.1 0 0.0 2444 Liposarcoma 15 0.3 1 1.6 1265 Myeloid sarcoma (leukemic infiltration of

extra-medullary tissue) 33 0.6 3 4.9

2445 Myelolipoma 5900 98.0 57 93.5

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2523 45.1 002 1418 25.3 003 Satisfactory 1438 25.7 004 173 3.1 005 Unsatisfactory 43 0.8

Cas

e #

2012

-40

Diagnosis (2056) Angiosarcoma PIP Participants PIPW Participants Code Diagnosis No. % No. % 2056 Angiosarcoma 5880 97.8 46 75.4 1944 Epithelioid hemangioendothelioma 83 1.4 12 19.7 1341 Metastatic sarcoma 13 0.2 0 0.0 2811 Poorly differentiated hepatocellular

carcinoma 34 0.6 3 4.9

Technical Quality of Slide

PIP Participants Rating Glass Slide Evaluation No. % 001 Excellent 2683 48.1 002 1443 25.9 003 Satisfactory 1344 24.1 004 95 1.7 005 Unsatisfactory 11 0.2

5

2012 PIP/PIPW-D DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide Evaluation DiagnosisPIP ParticipantsPIPW ParticipantsCodePIP ParticipantsRating

Glass Slide EvaluationPSR Cover.pdfPIP-DPerformance ImprovementProgram in Surgical Pathology